newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

  • Aligos Therapeutics announced positive data from five presentations at the AASLD The Liver Meeting 2026 held November 5–9, 2026, in Denver, CO.
  • Long-term follow-up data for pevifoscorvir sodium showed reduced pro-inflammatory cytokines in nine HBeAg+ participants after 96 weeks of monotherapy, with increases observed during subsequent entecavir treatment.
  • Preclinical data demonstrated that pevifoscorvir's active moiety, ALG-001075, inhibited relaxed circular DNA and double-stranded linear DNA formation with greater potency than nucleos(t)ide analogs tenofovir or entecavir.
  • These findings suggest capsid assembly modulators may better prevent HBV DNA integration than nucleos(t)ide analogs, potentially reducing risks of fibrosis, cirrhosis, and hepatocellular carcinoma.
  • Preclinical data for ALG-170675, a next-generation HBV antisense oligonucleotide, showed deeper HBsAg knockdown than bepirovirsen in an AAV-HBV mouse model.
  • ALG-170675 has advanced to Phase 1 clinical studies in China in partnership with Amoytop.
  • In vitro data for the hepatitis delta virus program indicated that ASO ALG-215007 potently inhibited HDV replication across multiple cellular systems.
  • Five specific abstracts detailing these findings are scheduled for presentation on November 7 and 8, 2026, under Hepatitis B and Other Infections sessions.
  • Presentation details are available on the Aligos Therapeutics website following the conference.
Company
Aligos Therapeutics
Keywords
Nasdaq:ALGS, Aligos Therapeutics